Drug Interactions Corner

Back to articles

Gemfibrozil and atorvastatin increase repaglinide concentrations


Gemfibrozil causes long-lasting inhibition of cytochrome P450 (CYP) 2C8 metabolism and increases repaglinide (Prandin—Novo Nordisk) concentrations, but the full extent of this interaction depends on the patient’s individual SLCO1B1 genotypes. Atorvastatin (Lipitor—Pfizer) slightly increases repaglinide concentrations, most likely via inhibition of the SLCO1B1-encoded organic anion transporting polypeptide 1B1 (OATP1B1).